June 2020 ZOHU Call

Overview
  • Overview of the Meat and Poultry Processing Interim Guidance from the Centers for Disease Control and Prevention and the Occupational Safety and Health Administration
  • Assessing the Risks of Reverse Zoonotic Transmission of SARS-CoV-2 from Humans to North American Wildlife
  • Development of Rabies Post-Exposure Prophylaxis Quality Improvement Program at a Multi-Hospital Health System

Date: Wednesday, June 3, 2020

Time: 2:00-3:00 pm (Eastern Time)

Join the live webinar:

See and hear the presentations and ask questions online.
Please click the link below and enter the password: zohujun3
https://cdc.zoomgov.com/j/1603935234?pwd=V3R6dDFJdmJMVmViN3VqWFYxeG5iQT09external icon

Listen only by phone:
Dial US: +1 669 254 5252 or +1 646 828 7666
Webinar ID: 160 393 5234
Password: 544746
International numbers available: https://cdc.zoomgov.com/u/aKOy6fkkpexternal icon
iPhone one-tap :US: +16692545252,,1603935234#,,1#,544746#  or +16468287666,,1603935234#,,1#,544746#

CE Materials:

Continuing Education for ZOHU Calls

Course access code: onehealth2020

Webcast: WC2962-060320
Origination Date: June 3, 2020
Expiration Date: July 6, 2020

Web-on-Demand: WD2962-060320
Origination Date: July 7, 2020
Expiration Date: July 7, 2022

Presentations:

One Health News from CDC
Casey Barton Behravesh, MS, DVM, DrPH, DACVPM
Captain, U.S. Public Health Service
Director, One Health Office
Centers for Disease Control and Prevention
dlx9@cdc.gov

Overview of the Meat and Poultry Processing Interim Guidance from the Centers for Disease Control and Prevention and the Occupational Safety and Health Administration
Suzanne Tomasi, DVM, MPH, DACVPM
Epidemiologist
Field Studies Branch
Respiratory Health Division
National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
yxc4@cdc.gov

Assessing the Risks of Reverse Zoonotic Transmission of SARS-CoV-2 from Humans to North American Wildlife
Jonathan Sleeman, MA, VetMB, Dipl. ACZM, MRCVS
Center Director
National Wildlife Health Center
United States Geologic Survey
jsleeman@usgs.gov

Development of Rabies Post-Exposure Prophylaxis Quality Improvement Program at a Multi-Hospital Health System
Joshua T. Swan, PharmD, MPH, FCCM, BCPS
Associate Professor of Pharmacy in Surgery and Outcomes Research
Houston Methodist Hospital
JTSwan@houstonmethodist.org

Resources

Overview of the Meat and Poultry Processing Interim Guidance from the Centers for Disease Control and Prevention and the Occupational Safety and Health Administration

Assessing the Risks of Reverse Zoonotic Transmission of SARS-CoV-2 from Humans to North American Wildlife

Development of Rabies Post-Exposure Prophylaxis Quality Improvement Program at a Multi-Hospital Health System

Overall series objectives:

  1. Describe 2 key points from the presentation.
  2. Describe how a multisectoral One Health approach can be applied to the presentation topic.
  3. Identify an implication for animal and human health.
  4. Identify a One Health approach strategy for prevention, detection, or response to public health threats.
  5. Identify 2 new resources from CDC partners.

Disclosures:

In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Joshua T. Swan and he wishes to disclose that an advisor board stipend was paid to his employer by Kedrion Biopharmacueticals, and investigator-initiated research funding was paid to his employer by Grifols (both are manufacturers of rabies immune globulin).

The planning committee reviewed content to ensure there is no bias.

The presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept commercial support for this activity.